BPC 157: Comprehensive Review of the Body Protection Compound's Benefits, Safety, and Regulatory Status

BPC 157 has demonstrated pleiotropic beneficial effects across numerous preclinical models including tissue injury, inflammatory bowel disease, and CNS disorders. Its safety profile appears favorable with few reported side effects. However, it has not been approved by the FDA or other regulatory authorities due to the absence of sufficient human clinical studies. WADA temporarily banned it in 2022, though it is no longer on the banned list. The review also documents significant commercial and patent interest in the compound.

Literature and patent review covering the biological activities, mechanisms of action, toxicity data, and patent landscape for BPC 157.

BPC 157 is one of the most popular peptides in the wellness and sports performance communities, widely sold online despite no regulatory approval. This review provides a needed evidence-based assessment — acknowledging the promising preclinical data while emphasizing the critical gap: no controlled human trials. For the many people already using this peptide, and for researchers, this review clarifies what is known versus assumed.

BPC 157 represents a broader phenomenon in peptide therapeutics: compounds with impressive preclinical data that gain widespread public use before undergoing proper clinical validation. The gap between animal studies and human evidence is a critical issue in peptide medicine. BPC 157's journey — from gastric juice discovery to online marketplace to WADA scrutiny — illustrates the challenges of regulating peptides in the supplement era.

This is a literature review, not a clinical study. All reported therapeutic effects come from preclinical (animal) models, which may not translate to humans. The lack of randomized controlled trials in humans is the fundamental limitation — no matter how promising animal data appears. The safety profile, while favorable in preclinical models, has not been rigorously assessed in human populations.